EP4626465A1 — Methods for treating late onset pompe disease in pediatric patients
Assigned to Amicus Therapeutics Inc · Expires 2025-10-08 · 1y expired
What this patent protects
Provided herein are methods for treating Pompe disease in pediatric patients by administering to a subject a population of recombinant human acid α-glucosidase molecules or a pharmaceutical composition or formulation thereof, and a pharmacological chaperone.
USPTO Abstract
Provided herein are methods for treating Pompe disease in pediatric patients by administering to a subject a population of recombinant human acid α-glucosidase molecules or a pharmaceutical composition or formulation thereof, and a pharmacological chaperone.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.